Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
dendritic cell-gp100-MART-1 antigen vaccine
BIOLOGICAL
2 trials
Sponsors
Genzyme, a Sanofi Company
, National Cancer Institute (NCI)
Conditions
Melanoma (Skin)
Recurrent Melanoma
Stage III Melanoma
Stage IV Melanoma
Phase 1
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
NCT00004025
Genzyme, a Sanofi Company
Melanoma (Skin)
Start: 1999-03-31
Target: 36
Updated: 2014-01-06
Phase 2
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Completed
NCT00019890
National Cancer Institute (NCI)
Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
End: 2007-03-31
Updated: 2024-03-04